Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Anti-CD19 CAR T cells administration was feasible in a child with primary hepatitis B infection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia†

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Asparaginase Enzyme Activity Levels and Toxicity in Childhood Acute Lymphoblastic Leukemia: a NOPHO ALL2008 study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

Vis graf over relationer

BACKGROUND: Treatment-related osteonecrosis (ON) is a serious complication of treatment of acute lymphoblastic leukemia (ALL).

PROCEDURE: This study included 1,489 patients with ALL, aged 1-45 years, treated according to the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol, using alternate-week dexamethasone during delayed intensification, with prospective registration of symptomatic ON. We aimed at comparing risk factors, timing, and clinical characteristics of ON in children and young adults.

RESULTS: ON was diagnosed in 67 patients, yielding a 5-year cumulative incidence of 6.3%, but 28% in female adolescents. Median age at ALL diagnosis was 12.1 years and 14.9 years for females and males, respectively. At ON diagnosis, 59 patients had bone pain (91%) and 30 (46%) had multiple-joint involvement. The median interval between ALL and ON diagnosis was significantly shorter in children aged 1.0-9.9 years (0.7 years [range: 0.2-2.1]) compared with adolescents (1.8 years [range: 0.3-3.7, P < 0.001]) and adults (2.1 years [range: 0.4-5.3, P = 0.001]). Female sex was a risk factor in adolescent patients (hazard ratio [HR] = 2.1, 95% confidence interval [CI]: 1.1-4.2) but not in children aged 1.1-9.9 years (HR = 2.4, 95% CI: 0.9-6.2, P = 0.08) or adults aged 19-45 years (HR = 1.1, 95% CI: 0.3-4.0). Age above 10 years at ALL diagnosis (odds ratio [OR] = 3.7, P = 0.026) and multiple joints affected at ON diagnosis (OR = 3.4, P = 0.027) were risk factors for developing severe ON.

CONCLUSION: We provide a detailed phenotype of patients with ALL with symptomatic ON, including description of risk factors and timing of ON across age groups. This awareness is essential in exploring measures to prevent development of ON.

OriginalsprogEngelsk
TidsskriftPediatric Blood & Cancer
Vol/bind65
Udgave nummer10
Sider (fra-til)e27300
ISSN1545-5009
DOI
StatusUdgivet - okt. 2018

ID: 55742032